AI in Life Science Market Report Scope & Overview:

The AI in Life Science Market was valued at USD 17.35 Billion in 2025 and is expected to reach USD 159.02 Billion by 2035, growing at a CAGR of 24.80% from 2026-2035.

The AI in Life Science Market comprises compute infrastructure, foundation models and purpose-built software that pharmaceutical, biotechnology and diagnostic organizations deploy across drug discovery, clinical development and laboratory operations. Deal structures rarely resemble a simple software sale: vendors increasingly enter co-development lab arrangements, milestone-bearing data licenses and equity-linked partnerships rather than per-seat subscriptions. End-to-end platforms combining model, compute and domain workflow currently capture the largest share of spending, since buyers want a vendor accountable for a full pipeline rather than a single point tool. North America anchors global demand on the strength of its concentrated pharmaceutical R&D base, while Asia Pacific scales fastest as governments fund local AI-drug-discovery infrastructure.

⮞Schrödinger and Bristol Myers Squibb announced on August 5, 2026 a strategic collaboration and software agreement to deploy Bunsen, Schrödinger's agentic AI co-scientist, at scale across BMS's computational chemistry programs, alongside its RetroSynth synthesis-planning platform. A large-scale software deployment of that kind inside an established pharmaceutical customer illustrates how deeply AI platforms are now embedding into everyday discovery workflows rather than staying confined to pilot projects.

U.S. AI in Life Science Market Outlook

The U.S. AI in Life Science Market was valued at USD 7.32 Billion in 2025 and is expected to reach USD 63.68 Billion by 2035, growing at a CAGR of 24.15% from 2026-2035.

The U.S. AI in Life Science Market concentrates around the country's largest pharmaceutical and biotechnology R&D hubs, where compute-infrastructure providers, model developers and sponsors increasingly co-locate research teams rather than working through arm's-length vendor contracts. Large pharmaceutical companies are committing multi-year partnerships valued at several hundred million US dollars with AI infrastructure providers to secure dedicated compute capacity ahead of competitors chasing the same discovery timelines. Academic medical centers and government laboratories remain a secondary buyer base, often piloting tools later adopted at commercial scale once validated in a research setting. The FDA's expanding AI-specific review pathways give sponsors a clearer route to bring AI-assisted diagnostics through review, reducing the evidentiary burden for each new submission.

⮞The FDA's AI-enabled medical device list had grown to more than 1,400 authorized devices as of its March 4, 2026 update, covering authorizations issued through December 30, 2025, with the majority concentrated in radiology. A device count of that size and growth rate gives U.S. life-science AI vendors a widening regulatory precedent to build subsequent submissions against.

By Offering, End-to-End Solutions Dominates the AI in Life Science Market and AI Technology Grows Fastest

End-to-end solutions lead the offering split because sponsors running a discovery-to-development pipeline want one accountable vendor spanning model, compute and domain workflow rather than integrating multiple point tools, each of which needs its own validation cycle. Vendors selling this way can bundle compute access with model fine-tuning and workflow software under a single contract, which simplifies procurement for sponsors seeking to limit the number of vendor relationships per discovery program. Large pharmaceutical buyers in particular favor this structure since it concentrates accountability for pipeline performance with a smaller number of strategic partners rather than a long tail of specialized suppliers.

AI technology itself, meaning the underlying foundation models and compute platforms sold separately from a packaged workflow, is growing fastest as infrastructure providers position directly as life-science partners rather than staying purely upstream. Compute providers entering through dedicated co-innovation labs are capturing budget that previously went to narrower software vendors, since sponsors now view model access and compute capacity as the scarcer resource relative to workflow software. That shift is pulling spending toward infrastructure-level offerings even as end-to-end platforms retain the largest absolute share of total offering revenue.

⮞Owkin and AstraZeneca announced on May 13, 2026 a three-year licensing agreement for K Pro, Owkin's agentic AI Scientist platform, giving AstraZeneca's decision-making teams end-to-end AI agents for competitive-intelligence analysis across pharmaceutical targets, assets and clinical trials. A multi-year AI-agent licensing structure of that kind, rather than a one-time software sale, illustrates why the AI technology offering category is outpacing packaged end-to-end sales.

By Application, Clinical Dominates the AI in Life Science Market and Non-Clinical Grows Fastest

Clinical applications, spanning drug discovery, medical imaging and diagnostics, clinical trials and precision medicine, account for the largest application share because these are the use cases most directly tied to a sponsor's core revenue-generating pipeline rather than a supporting back-office function. Budget owners inside pharmaceutical and biotechnology organizations prioritize clinical-facing AI investment first since faster trial enrollment or earlier target identification translates directly into shortened time-to-market for a priority pipeline asset. That direct line to pipeline economics keeps clinical applications the largest category even as non-clinical tooling expands rapidly from a much smaller current base.

Non-clinical applications, covering R&D support, data analytics and reporting, manufacturing and quality assurance, and regulatory affairs, are growing fastest as organizations extend AI adoption beyond the discovery bench into the operational functions that support it. Manufacturing and quality teams adopting AI-assisted anomaly detection and regulatory affairs groups using AI to draft and track submission documentation are newer buyers relative to clinical research groups, giving this category much more headroom for percentage growth over the coming decade. As AI tooling matures and proves reliable in clinical settings, operational teams are increasingly willing to adopt comparable tools for their own internal workflows and reporting needs.

⮞PathAI received 510(k) clearance from the FDA on June 30, 2025 for its AISight Dx digital pathology platform to support primary diagnosis in clinical settings, covering use with two named slide-scanner systems and including a predetermined change-control plan for future updates. A clinical-diagnosis clearance of that kind illustrates why clinical applications continue to command the largest share of application-level AI spending industry-wide.

By Component, Software Dominates the AI in Life Science Market and Services Grows Fastest

Software holds the larger component share because the models, platforms and analytics tools themselves represent the core intellectual property that life-science AI vendors sell and that buyers ultimately license or subscribe to for recurring use. Once a sponsor commits to a given software platform, switching costs tend to be high given the validation and integration work already invested, which sustains durable software revenue even as implementation projects around it come and go. Vendors with strong proprietary datasets underpinning their software are able to command premium pricing that a comparable services engagement, priced mainly on billable labor hours, typically cannot match on margin.

Services are growing fastest as more sponsors, particularly mid-size biotechnology companies without large in-house AI teams, need implementation, model customization and ongoing support to get software deployed into a validated, regulator-ready workflow. This services layer includes everything from initial platform configuration to continuous model retraining as a sponsor's own data accumulates over time, work that software licensing alone does not cover under a standard subscription contract structure. As adoption spreads beyond AI-native organizations to more traditional pharmaceutical operators that lack internal AI expertise, the services category is capturing a growing share of first-time implementation spending across the broader market and buyer base.

⮞Recursion Pharmaceuticals disclosed on February 26, 2026 that it had reached its fifth milestone under its Sanofi collaboration, triggering USD 134 million in payments and pushing cumulative partnership revenue above USD 500 million, extending its cash runway into early 2028. Milestone-structured software and service revenue of that scale shows how deeply platform vendors are now embedded in sponsors' ongoing discovery operations rather than selling a one-time tool.

By End User, Pharmaceutical Companies Dominate the AI in Life Science Market and Biotechnology Companies Grow Fastest

Pharmaceutical companies account for the largest end-user share because they run the largest discovery and development budgets in the industry and have the scale to fund enterprise-wide AI platform deployments spanning multiple therapeutic programs simultaneously. These organizations also carry the regulatory and commercial infrastructure needed to take an AI-assisted discovery or trial-design output all the way through approval, which smaller organizations often cannot do independently without an established pharmaceutical partner alongside them. That combination of budget scale and end-to-end development capability keeps pharmaceutical companies the anchor customer segment for most major life-science AI vendors.

Biotechnology companies are growing fastest as a newer generation of AI-native biotechs builds its entire discovery operation around AI platforms from founding, rather than retrofitting AI tools onto an established legacy workflow built for an earlier generation of drug development. These companies frequently structure vendor relationships as equity-linked or milestone-bearing partnerships rather than straightforward software purchases, aligning vendor incentives directly with program success rather than subscription renewal. As more biotechnology companies reach clinical-stage maturity using this AI-native approach, this end-user category is expected to keep expanding faster than the broader pharmaceutical-anchored market overall.

⮞Dassault Systèmes completed its roughly USD 2 billion acquisition of ArisGlobal in October 2026, connecting an AI-native compliance platform processing more than 12 million patient safety reports a year, serving half of the top 50 global biopharma companies, into its broader life-science platform. An enterprise acquisition of that scale aimed squarely at large pharmaceutical customers illustrates how aggressively capital is now flowing toward serving established pharmaceutical end users rather than only AI-native biotechnology ventures.

Regional Analysis

North America AI in Life Science Market Insights

Holding a 47.60% share in 2025, North America leads the market on the strength of the world's most concentrated pharmaceutical R&D base, deep venture and corporate capital pools, and a compute-infrastructure ecosystem already headquartered in the region. The United States supplies 88.70% of regional output, anchored by the country's largest pharmaceutical companies committing billion-dollar, multi-year AI infrastructure partnerships directly rather than purchasing software incrementally. Canada contributes a smaller but growing share, supported by academic research institutions and AI-native biotechnology startups building discovery platforms from the ground up. That combination of capital depth and R&D concentration keeps North America the largest region despite Asia Pacific's faster percentage growth.

U.S. pharmaceutical and compute-infrastructure companies are increasingly co-locating research teams inside shared innovation labs rather than managing arm's-length vendor contracts, a structural shift that is deepening regional spending even without proportional headcount growth. Regulatory clarity from the FDA's expanding AI-specific review pathways is giving North American sponsors a faster, lower-risk route to commercialize AI-assisted diagnostics than sponsors in markets still awaiting equivalent guidance. Canadian and U.S. academic medical centers continue to serve as an early validation ground for tools that later scale into commercial deployment. Even with Asia Pacific's capacity build-out accelerating, North America's infrastructure and regulatory head start are expected to keep it the leading region through 2035.

⮞Aidoc secured FDA clearance on January 21, 2026 for what it calls the industry's first comprehensive foundation-model AI triage platform, combining eleven newly cleared indications with three previously cleared ones into a single abdomen-CT workflow after earning Breakthrough Device status in August 2025. A regulatory clearance of that breadth for a single foundation-model platform underscores why North America continues to out-invest every other region in life-science AI capacity.

Asia Pacific AI in Life Science Market Insights

Asia Pacific is the fastest-growing region, projected to expand at a CAGR of approximately 29.70% from 2026 to 2035, as China, Japan, South Korea and India scale local AI-drug-discovery capacity through a combination of public funding programs, domestic platform developers and partnerships with global sponsors. Japan's biopharma support policy directs public funding toward bioclusters, rare-disease trials and manufacturing capacity, while regional pharmaceutical companies increasingly contract AI-native developers to design and optimize drug candidates. That combination of public funding and commercial partnership activity gives Asia Pacific the fastest expansion trajectory among tracked regions.

India is emerging as a lower-cost AI-model-training and data-annotation hub for global life-science sponsors, complementing China's and Japan's more capital-intensive discovery platforms with scalable operational capacity. South Korea and Australia remain smaller contributors but are investing in regulatory sandboxes specifically designed to accelerate AI-enabled diagnostic approval timelines relative to conventional device review. Regional governments are treating AI-drug-discovery capacity as a strategic industrial priority rather than leaving capacity-building entirely to market forces, a posture distinct from how North American and European policymakers have approached the category. As this policy-backed capacity build-out continues, Asia Pacific's share of global AI-in-life-science spending is expected to keep rising through 2035.

⮞Insilico Medicine and SK Biopharmaceuticals announced on June 22, 2026 a collaboration with potential value of more than USD 2.5 billion, applying Insilico's Pharma.AI engine to design and optimize drug candidates, with only USD 18 million tied to upfront and near-term milestone payments. A heavily backloaded, platform-based structure of that kind illustrates how Asia Pacific sponsors are contracting for AI-driven discovery capacity and tying most of the value to program progress.

Europe AI in Life Science Market Insights

Europe's market is shaped as much by regulatory architecture as by commercial demand, with Germany anchoring regional activity through its large pharmaceutical manufacturing base and a dense network of academic life-science institutes already experimenting with AI-assisted discovery tools. The European Union's AI Act is pushing pharmaceutical and medical-device companies toward structured compliance programs covering AI literacy, risk classification and documentation well ahead of most U.S. sponsors. France and the United Kingdom contribute meaningful demand, particularly from government-backed genomics initiatives relying on AI-driven analysis pipelines. That regulatory architecture, still being finalized in parts, is shaping how quickly European sponsors can move from pilot deployment to full commercial-scale AI adoption.

Pharmaceutical and medical-device companies operating across multiple EU member states are consolidating AI governance functions centrally to manage compliance obligations efficiently rather than duplicating documentation market by market. European sponsors continue to favor vendors able to demonstrate AI Act-aligned risk management and transparency documentation as a condition of procurement, which is reshaping competitive dynamics in favor of larger, compliance-resourced vendors over smaller point-solution providers. Cross-border research consortia remain a meaningful funding channel for early-stage AI tool validation across the region. As the regulatory framework matures and sponsors adapt their internal processes to it, European AI adoption is expected to accelerate from its current, comparatively measured pace.

⮞EU regulators and life-science companies are actively navigating AI literacy requirements under Article 4 of the EU AI Act alongside annual AI observatory reporting obligations that pharmaceutical regulators across the bloc published for the first time in late 2025. Compliance infrastructure of that depth, built specifically for AI governance, illustrates how significantly regulatory architecture is shaping European life-science AI adoption relative to other regions.

MEA & Latin America AI in Life Science Market Insights

The Middle East and Africa region is building AI-in-life-science capacity through sovereign-backed partnerships rather than organic private-sector growth, with the United Arab Emirates and Saudi Arabia leading regional investment through dedicated biotech initiatives. Abu Dhabi's innovation centers signed agreements covering drug discovery and preventive health, positioning the emirate as a regional hub rather than simply an importer of AI tools developed elsewhere. South Africa and other African markets remain earlier-stage, relying mainly on imported AI tools rather than local platform development.

Latin America's AI-in-life-science activity centers on Brazil, where government-backed research centers are receiving federal investment to build health-innovation and drug-discovery capacity locally rather than depending entirely on imported platforms. Smaller biotechnology ventures across the region are raising early-stage funding for AI-assisted drug discovery focused on regionally relevant disease areas, including neglected tropical diseases that larger global sponsors deprioritize commercially. Mexico and Argentina contribute smaller but growing venture activity in AI-driven biotechnology, often through newly formed regional investment vehicles. Currency volatility and limited local capital markets continue to make Latin America more dependent on international partnerships than other fast-growing regions, even as local research investment expands.

⮞Bahrain's Mumtalakat and SandboxAQ announced a three-year collaboration on October 27, 2025 valued at more than USD 1 billion in new biotech assets, licensing SandboxAQ's AI-powered molecular simulation software to position Bahrain as a regional life-science hub. A sovereign-wealth-backed commitment of that size illustrates how directly public capital is now shaping adoption across the Middle East and Africa.

Market Dynamics

Growth Drivers: Infrastructure-scale partnerships and regulatory precedent are accelerating enterprise adoption

The strongest driver is the shift from pilot-scale AI experimentation toward infrastructure-scale, multi-year partnerships that commit dedicated compute capacity and shared research teams rather than a software license alone. Large pharmaceutical sponsors are treating AI infrastructure access as a strategic asset worth securing years ahead of need, mirroring how earlier generations of drug developers once competed for manufacturing capacity rather than discovery tooling. Compute-infrastructure providers entering life science directly through co-innovation labs are reinforcing this shift, since they bring capital and technical teams a conventional software vendor relationship would not include.

A second driver is accumulating regulatory precedent that gives sponsors a clearer, lower-risk path to commercialize AI-assisted tools, reducing the evidentiary burden for each new submission. Authorities expanding AI-specific review pathways are reducing the perceived regulatory risk that previously made some sponsors hesitant to commit capital to AI-dependent discovery or diagnostic programs. Government-funded local capacity-building programs in several Asian markets are reinforcing this momentum by treating AI-drug-discovery infrastructure as strategic industrial policy rather than leaving capacity entirely to private investment. As regulatory and policy precedent continues to accumulate across more jurisdictions, enterprise adoption is expected to keep outpacing earlier technology-adoption cycles in the sector.

⮞Japan's Cabinet Office approved a 330 billion yen support package for drug discovery and the biopharma sector in January 2026, directing roughly 50 billion yen toward bioclusters and biotech infrastructure alongside funding for rare-disease trials and advanced-therapy manufacturing. A direct government funding commitment of that scale demonstrates how national policy is now actively accelerating AI-enabled life-science capacity rather than waiting for private markets alone to build it.

Restraints: Data privacy exposure and unsanctioned tool use create governance risk

A persistent restraint is the tension between the clinical and genomic data richness that makes life-science AI valuable and the privacy exposure that comes with aggregating that same data at scale across institutional boundaries and national borders alike. Sponsors and health systems must navigate overlapping privacy regimes across jurisdictions, and a single data-handling misstep can trigger regulatory scrutiny that stalls an otherwise promising AI program for several months. Smaller biotechnology companies without dedicated data-governance teams are particularly exposed to this risk relative to large pharmaceutical organizations that can fund dedicated compliance infrastructure and legal review capacity internally.

A second restraint is a persistent gap between approved AI policy and actual tool usage among frontline researchers and clinicians, which creates risk that formal procurement processes do not fully capture. Unsanctioned tool use inside research and clinical organizations means some AI-driven value is being generated and consumed entirely outside vendor contracts and governance frameworks that market-sizing data can observe, understating formal market figures while simultaneously creating uncontrolled data-handling risk. Until governance policy and actual usage patterns converge, organizations face a persistent mismatch between what leadership believes is happening and what is actually occurring on the ground.

⮞A Wolters Kluwer survey conducted in December 2025 found that 40% of healthcare professionals had encountered unauthorized AI tools at work and nearly 20% admitted using them, with half citing the need for faster workflows and one in ten reporting direct patient-care use. Unsanctioned AI use at that scale illustrates the governance gap that formal market data and procurement processes alike are currently struggling to capture.

Opportunities: Sovereign capital and AI-native biotechnology ventures open new growth channels

A major opportunity lies in sovereign and government-backed capital increasingly flowing into AI-driven life-science infrastructure outside the traditional venture-capital and corporate-R&D funding channels that have historically dominated the sector. State-linked investment vehicles in the Gulf region and parts of Asia are treating AI-drug-discovery capacity as a strategic diversification asset, giving vendors a new category of large, patient-capital customers distinct from venture-backed biotechs chasing shorter return horizons. Vendors that can structure partnerships suited to sovereign-capital timelines and strategic objectives, rather than standard enterprise software terms, stand to capture a growing share of this emerging funding pool.

A second opportunity lies in the rise of AI-native biotechnology companies built from founding around AI platforms rather than retrofitting AI onto legacy discovery workflows, a structurally different and faster-growing customer type than established pharmaceutical incumbents of any size. These companies frequently prefer milestone-bearing or equity-linked vendor relationships over conventional software licenses, aligning vendor incentives directly with program success rather than subscription renewal alone. Vendors willing to structure deals this way, accepting deferred or contingent payment in exchange for deeper program alignment, are positioned to capture a disproportionate share of this emerging, AI-native segment as it scales toward clinical maturity.

⮞Insilico Medicine received a USD 5 million milestone payment from Menarini Group on February 3, 2026 after first-in-patient dosing of MEN2501, an AI-discovered cancer drug licensed to Menarini in January 2025 under an agreement worth more than USD 550 million in combined value. A milestone-bearing licensing structure of that kind illustrates the deal architecture increasingly available to AI-native drug discovery vendors positioning for both large pharmaceutical incumbents and biotechnology ventures alike.

AI in Life Science Market Key Players

• NVIDIA Corporation

• Alphabet Inc. (Google Cloud / Isomorphic Labs)

• Tempus AI, Inc.

• Dassault Systèmes

• Recursion Pharmaceuticals, Inc.

• Schrödinger, Inc.

• Microsoft Corporation

• Insilico Medicine

• Owkin, Inc.

• PathAI, Inc.

• Aidoc Medical Ltd.

• Qure.ai Technologies

• SOPHiA GENETICS SA

• SandboxAQ

AI in Life Science Market Report Scope: